Immune cells are not bystanders in Parkinson's disease
A discovery from University College London has illuminated one of medicine's quiet mysteries: how Parkinson's disease travels from the gut to the brain, often decades before a tremor betrays its presence. Immune cells called macrophages, designed to protect, instead engulf misfolded proteins and set in motion a chain of events that carries disease across the body's most guarded frontier. The finding, published in Nature, does not merely explain a mechanism — it reveals a window of time, long invisible to medicine, in which intervention might one day be possible.
- Two-thirds of Parkinson's patients suffer gut symptoms like severe constipation for decades before any movement disorder appears, yet medicine has had no way to act during that critical window.
- Gut macrophages — the body's own immune defenders — are now implicated as unwitting carriers, engulfing toxic alpha-synuclein proteins and triggering a cascade that dispatches T cells into the brain.
- When researchers reduced gut macrophages in mice before introducing the toxic protein, brain toxin levels dropped significantly and motor function improved, proving the pathway can be disrupted.
- The team is now investigating whether inflammatory markers in the blood could serve as early warning signals, potentially enabling diagnosis and preventive treatment years before neurological damage becomes irreversible.
Scientists at UCL's Dementia Research Institute have answered a question that has shadowed Parkinson's research for decades: how does the disease travel from the intestines to the brain? The answer, published in Nature, implicates the immune system's own foot soldiers — gut macrophages — as inadvertent carriers of the very pathology they are meant to neutralize.
The suspicion that Parkinson's begins in the gut is not new. One of the first brain regions the disease damages is the dorsal motor nucleus of the vagus nerve, which connects directly to the intestines. But the cellular mechanism of that journey was unknown until now. Using misfolded alpha-synuclein extracted from the brain tissue of deceased Parkinson's patients, researchers introduced the toxic protein into the small intestines of mice and watched what unfolded. Gut macrophages engulfed the alpha-synuclein, but in doing so their internal disposal systems broke down. These compromised cells then signaled T cells — immune fighters that normally hunt infection — which traveled from gut to brain, carrying the toxic protein with them.
The researchers confirmed the pathway's importance by disrupting it: mice with reduced gut macrophages showed significantly lower brain toxin levels and better motor function than controls, suggesting the immune-mediated transport is not incidental but central to disease progression.
What makes this discovery urgent is its timing. Between half and nearly all people eventually diagnosed with Parkinson's experience gastrointestinal symptoms — often severe constipation — years or even decades before their first tremor. That long pre-symptomatic period, currently invisible to clinical medicine, now looks like an opportunity. Lead author Dr. Soyon Hong described the macrophages not as passive bystanders but as active, potentially correctable participants in disease spread, and called for research into boosting their function so they respond correctly rather than propagating harm.
The team's next steps focus on whether inflammatory markers in the blood could flag at-risk individuals before symptoms emerge, and whether macrophage-targeted therapies could interrupt the gut-to-brain journey before irreversible neurological damage takes hold. The field has moved from asking whether Parkinson's spreads this way to understanding precisely how — and where it might be stopped.
Scientists at University College London's Dementia Research Institute have identified the cellular mechanism that allows Parkinson's disease to travel from the gut to the brain—a discovery that could reshape how the disease is detected and treated, potentially years before movement problems appear.
For decades, researchers have suspected that Parkinson's begins in the intestines rather than the brain. The clue lies in anatomy: one of the first brain regions damaged by the disease is the dorsal motor nucleus of the vagus nerve, a structure that maintains direct connections to the gut. Yet the pathway by which toxic proteins make that journey from intestine to brain remained a mystery. The new work, published in Nature, identifies the culprit: specialized immune cells called macrophages that normally protect the body but, in this case, inadvertently ferry disease-causing proteins across the barrier between gut and brain.
In their experiments, the researchers extracted misfolded alpha-synuclein—the toxic protein at the heart of Parkinson's pathology—from brain tissue of deceased patients with the disease. They then introduced small quantities of this patient-derived protein directly into the small intestines of mice and tracked what happened next. The gut macrophages, acting as the body's first line of defense, engulfed the alpha-synuclein. But in doing so, their internal waste-disposal systems became dysfunctional. These compromised macrophages then sent chemical signals to T cells, immune fighters that normally patrol for infection. These "gut-instructed" T cells subsequently traveled from the intestines into the brain, carrying the toxic protein with them.
The implications became clear when the researchers prevented this cascade. By reducing the number of gut macrophages before introducing alpha-synuclein into the mice's intestines, they observed significantly lower levels of the toxic protein in the brain compared to control animals. Motor function in these depleted-macrophage mice also improved, suggesting that blocking this immune-mediated transport could slow or halt disease progression.
The timing of this discovery matters enormously. Between 50 and 90 percent of people eventually diagnosed with Parkinson's experienced gastrointestinal symptoms—often severe constipation—decades before their first tremor or movement difficulty. Roughly two-thirds of patients fall into this "body-first" category, meaning their disease announces itself through the gut long before the brain shows obvious signs of damage. This window of time, currently invisible to medicine, represents an opportunity for intervention that does not yet exist.
Dr. Soyon Hong, one of the study's lead authors, framed the finding as a shift in how scientists should think about immune involvement in Parkinson's. Rather than viewing macrophages as passive bystanders, the research shows them as active participants in disease spread—but participants whose dysfunction might be correctable. "This presents an opportunity to think about how we can boost the function of the immune system and these cells, so that they respond in the correct manner and help to slow or stop the spread of disease," Hong said.
The team's next steps involve deeper investigation into how systemic immune dysfunction damages the brain and whether inflammatory markers in the blood could serve as early warning signals for Parkinson's. If such blood tests prove feasible, they could identify at-risk individuals years before symptoms emerge, opening the door to preventive treatments that target macrophage function before irreversible neurological damage occurs. For now, the research has moved the field from asking whether Parkinson's spreads from gut to brain to understanding precisely how—and, crucially, where intervention might interrupt that journey.
Notable Quotes
Our study shows that immune cells are not bystanders in Parkinson's; these gut macrophages are responding, albeit in a dysfunctional way. This presents an opportunity to think about how we can boost the function of the immune system and these cells, so that they respond in the correct manner and help to slow or stop the spread of disease.— Dr. Soyon Hong, Group Leader at the UK Dementia Research Institute at UCL
The Hearth Conversation Another angle on the story
So the immune system is actually helping the disease spread? That seems backwards.
It does, but it makes sense when you think about it. Macrophages are supposed to eat invaders and clean up debris. They engulf the toxic protein, but their internal machinery gets overwhelmed and breaks down. They can't properly dispose of what they've taken in.
And then they recruit other immune cells to help?
Exactly. They signal to T cells, which are part of the adaptive immune response. Those T cells then travel from the gut into the brain, carrying the protein with them. It's like calling for backup that ends up making things worse.
Why does this matter for treatment?
Because if you can stop the macrophages from engulfing the protein in the first place, or prevent them from signaling to T cells, you might block the entire pathway. In mice, reducing macrophages cut brain toxin levels significantly.
But people have gut symptoms for decades before Parkinson's shows up in the brain. How does that timeline work?
That's the crucial part. The disease is already traveling during those decades of constipation and digestive problems. You have a long window where the gut is symptomatic but the brain hasn't failed yet. If you could identify and treat people during that window, you might prevent the disease from ever reaching the brain.
So a blood test could catch this early?
That's what they're exploring next. If inflammatory markers in the blood correlate with this macrophage dysfunction, you could potentially screen people who have gut symptoms and intervene before any neurological damage happens.